top of page
autoimmunity-bg.jpg

ABOUT
AUTOIMMUNITY BIOSOLUTIONS

ABOUT

Next-Generation, Immuno-Corrective Therapy for Treatment of Autoimmune Diseases by Targeting a Novel, Fundamental Autoimmune Pathway Driven by Upregulation of the Soluble Interleukin 7 Receptor (sIL7R).

Autoimmunity BioSolutions (ABS) is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients in which the autoimmune pathology is driven by a SNP that enhances the expression of sIL7R.

Innovations to Dial Immunity
Control Autoimmunity and Treat Cancer

OUR VISION

First-Line Treatment for the Genetically-Defined Risk Population in Multiple Autoimmune Diseases.  

ABS’ anti-sIL7R therapy is being developed as a first-line treatment for patients of various autoimmune diseases defined by the presence of the SNP and high levels of sIL7R.

OUR MISSION

Delivering this Immuno-Corrective Therapy to Patients in Great Need of Improved Treatments.

ABS is committed to provide patients with an effective immuno-corrective therapy that bypasses the safety liabilities associated with immunosuppression.

Delivering New Therapies
bottom of page